Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial

Michael EJ Lean, W. S. Leslie, Alison C. Barnes et al. · The Lancet · 2017 · 2.1K citations · Full text

Medicine, Endocrinology, Family Medicine +13

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi et al. · New England Journal of Medicine · 2020 · 1.9K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction

Dalane W. Kitzman, Peter H. Brubaker, Timothy M. Morgan et al. · JAMA · 2016 · 879 citations · Full text

Medicine, Cardiology, Geriatric Medicine +11

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Sven Francque, Pierre Bédossa, Vlad Ratziu et al. · New England Journal of Medicine · 2021 · 721 citations · Full text

Medicine, Internal Medicine, Pharmacology +15

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association

Arteriosclerosis Thrombosis and Vascular Biology · 2022 · 645 citations

Medicine, Cardiology, Pathology +17